Critical Therapeutics, Inc.

Biopharma company reports initial data from launch of ZYFLO (zileuton tablets)

Published in Genetics and Environmental Business Week, March 16th, 2006

Critical Therapeutics, Inc., (CRTX), a biopharmaceutical company focused on the discovery, development, and commercialization of products for respiratory, inflammatory, and critical-care diseases, reported financial results for the fourth quarter and year ended December 31, 2005. The company also announced initial sales and prescriptions written for its first commercial product, ZYFLO (zileuton tablets).

ZYFLO was approved for marketing by the U.S. Food & Drug Administration (FDA) on September 28, 2005 and sales of the drug began in late October 2005.

"The U.S. launch of ZYFLO highlighted a quarter in which we made steady progress in advancing our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week

Source: Genetics and Environmental Business Week (2006-03-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry